Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

622P - Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Neeraj Agarwal

Citation

Annals of Oncology (2020) 31 (suppl_4): S507-S549. 10.1016/annonc/annonc275

Authors

N. Agarwal1, R. Evans2, K. Abrams3, P. Dequen-O'Byrne4, C. McCrea5, D. Muston6, C. Gresty7, S. Ghate8, L. Fan9, R. Hettle5, N. Hawkins3

Author affiliations

  • 1 Oncology/internal Medicine, Huntsman Cancer Institute, University of Utah, 84112 - Salt Lake City/US
  • 2 Health Economics, Visible Analytics, OX2 0DPT - Oxford/GB
  • 3 Health Technology Assessment, Visible Analytics, Oxford/GB
  • 4 Health Economics, Visible Analytics, Oxford/GB
  • 5 Health Economics And Payer Evidence, AstraZeneca, CB4 0WG - Cambridge/GB
  • 6 Center For Observational And Real-world Evidence, Merck & Co., Inc., 7033 - Kenilworth/US
  • 7 Statistics, AstraZeneca, Cambridge/GB
  • 8 Center For Observational And Real-world Evidence, Merck & Co., Inc., 07033 - Kenilworth/US
  • 9 Center For Observational And Real-world Evidence, Merck & Co., Inc., Kenilworth/US
More

Resources

Abstract 622P

Background

In oncology trials, patients switching from the comparator to the experimental treatment may lead to underestimation of the ‘true’ OS benefit for the experimental treatment. By adjusting for switching, further insight can be gained into OS benefit. In the phase 3 PROfound study (NCT02987543) of olaparib versus physician’s choice of new hormonal agent (pcNHA) in patients with metastatic castration-resistant prostate cancer and a homologous recombination repair gene alteration, patients in the pcNHA arm were eligible to receive olaparib after progression assessed by blinded independent central review. We explored the impact of switching on the interim OS results for Cohort A in PROfound using five statistical approaches, including simple and more complex methods.

Methods

Following guidance from health technology assessment agencies and the European Medicines Agency, the switching-adjustment methods comprised two simple methods of 1) excluding patients in the pcNHA arm who received subsequent olaparib, 2) censoring patients in the pcNHA arm on receiving subsequent olaparib, and three more complex methods of 3) rank preserving structural failure time model (RPSFTM), 4) inverse probability of censoring weights (IPCW), and 5) two-stage estimation (TSE).

Results

At the interim analysis, the OS hazard ratio (HR) in Cohort A was 0.64 (95% confidence interval [CI] 0.42–0.97), with 61% of patients randomized to pcNHA having switched to olaparib. With simple methods, the switching-adjusted HRs (95% CI) ranged from 0.36 (0.20–0.64) to 0.63 (0.35–1.13). The more complex methods of RPSFTM and IPCW yielded HRs of 0.41 (0.22–0.77) to 0.52 (0.28–0.95); the TSE method could not be reliably performed as a suitable secondary baseline was not identified.

Conclusions

This analysis shows that the effect of olaparib versus pcNHA is likely to be underestimated if switching is not adjusted for, with all methods demonstrating a meaningful benefit in interim OS for olaparib. RPSFTM and IPCW provided more clinically credible results than alternative methods. Limitations include the number of ‘unswitched’ patients in the pcNHA arm and the assumptions required of each method. Further switching analyses on the final OS data are planned.

Clinical trial identification

NCT02987543 (release date 19 October 2016).

Editorial acknowledgement

Legal entity responsible for the study

AstraZeneca and Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth,NJ, USA.

Funding

AstraZeneca and Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA.

Disclosure

N. Agarwal: Advisory/Consultancy: Argos; Advisory/Consultancy: Clovis; Advisory/Consultancy: Foundation One; Advisory/Consultancy: Astellas; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Nektar; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Exelixis; Advisory/Consultancy, Research grant/Funding (institution): EMD Serono; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Genentech; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Medivation; Research grant/Funding (institution): Active Biotech; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Calithera; Research grant/Funding (institution): GlaxoSmithKline; Research grant/Funding (institution): Celldex; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution): Janssen; Research grant/Funding (institution): New Link Genetics; Research grant/Funding (institution): Prometheus; Research grant/Funding (institution): Rexahn; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Tracon. R. Evans: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Visible Analytics. K. Abrams: Advisory/Consultancy: AstraZeneca; Research grant/Funding (self): UK National Institute for Health Research; Full/Part-time employment: University of Leicester; Advisory/Consultancy: Visible Analytics. P. Dequen-O'Byrne: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Visible Analytics. C. McCrea: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. D. Muston: Full/Part-time employment: Merck. C. Gresty: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. S. Ghate: Full/Part-time employment: Merck. L. Fan: Full/Part-time employment: Merck. R. Hettle: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. N. Hawkins: Advisory/Consultancy: AstraZeneca; Full/Part-time employment: University of Glasgow; Advisory/Consultancy: Visible Analytics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings